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ARTICLE OPEN
Factors influencing participation and long-term commitment to
self-monitoring of blood pressure in a large remote clinical trial:
The treatment in morning versus evening (TIME) study
Keeran Vickneson 1, Amy Rogers 2✉, Thineskrishna Anbarasan1, David A. Rorie3, Thomas M. MacDonald4 and Isla S. Mackenzie4
© The Author(s) 2021
This study investigates factors associated with active participation, and long-term commitment, to home blood pressure monitoring
(HBPM) in the TIME study, a remote clinical trial assessing the effectiveness of morning vs. evening dosing of antihypertensive
medications on cardiovascular outcomes in adults with hypertension. Participants reporting HBPM ownership were invited to
submit blood pressure (BP) measurements three-monthly. Factors associated with active participation (submitting at least one set
of BP measurements), and longer-term commitment (at least six sets of BP measurements), were analysed using multivariable
logistic regression. 11,059 participants agreed to provide BP measurements, of whom 7646 submitted. Active participation
was associated with age (adjusted odds ratio (AOR) per decade, 1.29; 95% CI 1.23–1.36), positive family history of hypertension
(AOR 1.11; 95% CI 1.01–1.21), number of antihypertensive medications (AOR, 1.10; 95% CI 1.04–1.16), and lower deprivation
(AOR per decile, 1.03; 95% CI 1.01–1.05). People with higher body mass index (BMI) and smokers were less likely to participate (AOR,
0.91 (per increase of 5.0 kg/m2) and 0.63 respectively; all p < 0.001). 3,655 participants (47.8%) submitted measurements beyond
one year. Non-modifiable risk factors – age (AOR per decade, 1.29; 95% CI 1.21–1.37) and positive family history of hypertension
(AOR, 1.15; 95% CI 1.03–1.27) – were positively associated with longer-term commitment. Higher BMI (AOR per 5.0 kg/m2, 0.89; 95%
CI 0.85–0.93), smoking (AOR 0.60, 95% CI 0.44–0.82) and higher baseline systolic blood pressure (AOR per mmHg, 0.99; 95% CI
0.98–0.99) were negatively associated. This study provides insight into factors that influence HBPM use.
Journal of Human Hypertension; https://doi.org/10.1038/s41371-021-00621-5
INTRODUCTION
Hypertension is a major risk factor for cardiovascular disease and is
the largest contributor to cardiovascular morbidity and mortality
worldwide [1, 2]. In the UK, control of hypertension in the
community has improved but remains sub-optimal despite greater
awareness and wide availability of effective treatment [3, 4].
One approach to bridging this gap is encouraging more active
involvement of patients in monitoring and managing their
hypertension with appropriate guidance from health professionals.
Trials of self-monitoring and hypertension management using
home blood pressure monitors (HBPMs) have shown significant
benefits in reducing elevated blood pressures [5, 6]. Home blood
pressure measurements are more reliable and more strongly
correlated with long-term complications of hypertension than
office-based measures [7].
Randomized controlled trials provide robust evidence on the
safety and clinical benefit of interventions [8]. However, the
limited external validity of trials is a frequent criticism [9, 10].
Patients with hypertension are more willing to participate in
antihypertensive drug trials if they are younger, non-smokers, or
have previously participated in research [11]. However, the
influence of baseline demographics on the likelihood of partici-
pating in a remote clinical trial is unknown. In theory, remote
studies should improve external validity by widening access and
may encourage participant retention by removing the burden of
physical face-to-face study visits [12–14].
The TIME study is an ongoing, prospective, randomized, open-
label, blinded end-point (PROBE) design clinical trial investigating the
effect of morning versus evening dosing of antihypertensive
medications on cardiovascular outcomes in 21,104 participants with
hypertension [13]. The study is conducted online via a secure
website. Study participants who reported owning an HBPM at study
entry were invited to submit BP measurements throughout the
study. In the UK, the use of HBPMs is increasing, with ~30–40% of
people with hypertension owning an HBPM [15, 16]. Previous
research on the TIME study found that participants with diabetes
mellitus and current smokers were less likely to report owning an
HBPM [17, 18]. Besides ownership, recognising factors that influence
active participation and long-term commitment to BP self-monitoring
may help tailor future HBPM interventions in the community.
In this study, we aim to identify participant-level demographics,
co-morbidities, socioeconomic factors and HBPM characteristics
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that influence active participation (defined as submitting at least
one weekly set of BP measurements) and longer-term commit-
ment (defined as submitting at least six sets of BP measurements)
to home BP self-monitoring in the TIME study.
METHODS
Study design and participants
Patients were eligible for enrolment in the TIME study if they were aged 18 or
over, receiving treatment for hypertension with one or more antihyperten-
sive drugs, and had a valid email address. Potential study participants were
enrolled in the study via a secure website (http://www.timestudy.co.uk).
Further details of the TIME study are described in the published study
protocol [13]. Participants who reported owning an HBPM were invited to
submit home BP measurements regularly throughout the study. All types and
brands of personal HBPMs were accepted.
The TIME study is a registered clinical trial (EudraCT 2011-001968-21,
ISRCTN18157641) with ethical approval (East of Scotland Research Ethics
Service 11/AL/0309).
Data collection
Baseline data collection in TIME included self-reported demographics,
blood pressure-lowering medication(s), and the presence of other co-
morbid conditions including angina, myocardial infarction (MI), chronic
obstructive pulmonary disease (COPD), impaired kidney function, periph-
eral vascular disease, arthritis, and cerebrovascular disease (transient
ischaemic attack or stroke), and Index of Multiple Deprivation (IMD). The
indices of multiple deprivation for England [19], Scotland [20], Wales [21],
and Northern Ireland [22] are area-based measures of relative socio-
economic deprivation. Postcode areas are ranked from most deprived to
least deprived. This ranking is then categorized into ten “deciles” (from
most deprived= 1 to least deprived= 10). Individual IMD decile score was
derived from residential postcodes using publicly available deprivation
data from the different constituent countries and then aggregated into a
combined IMD decile score. The TIME Study recruited participants via
numerous outreach strategies: advertisements, invitations from general
practitioners’ (GP), hospital clinics, and research study databases, etc. [23].
Participants were asked to provide information on how they heard about
the study.
An online form asked participants to identify the blood pressure monitor
that they owned. A combination of a drop-down menu and a free-text field
were available for participants to input the brand, manufacturer and model
of their HBPM. HBPMs were categorised by site (upper arm or wrist cuff),
validation status (listed as validated according to the British and Irish
Hypertension Society (BIHS) or by dabl Educational Trust) and retail price
(protocol as described in [18]). HBPMs of participants who indicated they
owned HBPMs but did not provide any further information were classified
as ‘unknown’.
Participants were provided with a detailed set of instructions on correctly
taking BP measurements using their own HBPM, following NICE Guidelines
[24]. Participants were instructed to take BP measurements in the sitting
position after a minimum of at least five minutes rest. A series of three
consecutive measurements in the morning and in the evening, continued for
at least four days, and ideally, up to seven days were requested. During the
follow-up period, participants were reminded via an automated email to
submit a set of home BP measurements at one week, four weeks, twelve
weeks, six months and every three months thereafter. For this study,
participant follow-up was censored three months after the last known BP
measurement before 1st May 2019.
All participant-identifiable data was securely stored on the TIME study
database. Data were anonymised before extraction for analysis.
Outcomes
The two primary outcomes used to evaluate the self-monitoring BP regime
were active participation and long-term commitment. Active participation
was defined as submitting at least one 4–7 day set of BP measurements after
consent to participate. Long-term commitment to the BP self-monitoring
protocol was defined as submitting at least six 4–7 day sets of BP
measurements post-consent, equivalent to 1 year of active participation.
Statistical analysis
Continuous data were described using means ± standard deviation (SD)
while categorical data were summarised by counts and percentages of
the total. Due to participant error in data reporting for BMI variable
captured via text-entry (calculated from height and weight) on the
online form, outlying data points for BMI were excluded from the
analysis. Shapiro-Wilk tests were performed to test for data normality
before excluding extreme data points (0.5% of either end of the
distribution). A total of 105 extreme data points for BMI were excluded.
Multiple imputation was used to impute missing values for age, BMI and
socioeconomic status (IMD decile).
A logistic regression model was constructed to determine which factors
were associated with active participation. Model variables included age,
sex, country (within the UK), smoking status, BMI, comorbidities, family
history of hypertension, number of antihypertensive medications, socio-
economic deprivation (IMD decile), recruitment strategy, and HBPM
validation status. A second multivariable logistic regression model was
constructed to ascertain the effects of the same variables and baseline
systolic home blood pressure measurement on the likelihood of long-term
commitment to BP-self monitoring.
Due to the unstructured nature of free-text entries of BP measurements
from participants, several entries were either implausible or incomplete. For
example, some participants may have only submitted 2 days of BP
measurements over a 7-day period. We hypothesized that participants who
submitted incomplete or implausible data may be sufficiently different from
those who submitted complete data to mask associations in the model. A
sensitivity analysis was therefore undertaken to assess if the quality of
submitted BP measurements would affect output from the logistic regression
model. For each participant, aberrant BP values were identified according to
the following criteria, previously defined by Bobrie et al. [25]: (a) diastolic
blood pressure (DBP) less than 40mm Hg or greater than 150mm Hg, (b)
systolic blood pressure (SBP) less than 60mm Hg or greater than 250mm Hg,
or (c) pulse pressure less than 10mm Hg. Home BP measurements were
considered valid and complete if:
1. At least two consecutive BP measurements were taken for each BP
recording
2. At least four days of both morning and evening BP measurements
were provided over seven days.
The logistic regression model was repeated after excluding BP
measurements that did not satisfy these predefined criteria.
All statistical analyses were performed using R version 3.5.0 and RStudio




A total of 21,104 participants were randomized in the TIME study.
Of these, 11,059 (52.4%) agreed to submit HBPM measurements
and were included in this analysis. The characteristics of these
participants are summarized in Table 1. Most of the participants
were from England (n= 9,919; 89.7%). Remaining participants
were from Scotland (n= 782; 7.1%), Wales (n= 355; 3.2%), and
Northern Ireland (n= 3; 0.03%). The mean age of the participants
randomized was 67.8 ± 8.8 years, of whom 6799 (61.5%) were
male, and 5562 (50.3%) were obese (BMI ≥ 30 kg/m2). 4579 (41.4%)
reported a current or past history of smoking. Diabetes (11.1%),
arthritis (9.3%), and stroke/TIA (6.2%) were the most frequently
reported co-morbidities. The type of HBPM owned could not be
interpreted and identified based on information entered by the
participant for 3820 (34.5%) participants.
Factors influencing active participation in home BP self-
monitoring
Of the 11,059 participants who agreed to submit HBPM measure-
ments, only 7646 (69.1%) had submitted at least one blood pressure
measurement at the time of analysis (Fig. 1). Participants were found
to be more likely to actively participate if they were older (adjusted
odds ratio (AOR) per decade, 1.29; 95% CI 1.23–1.36), had a positive
family history of hypertension (AOR, 1.11; 95% CI 1.01–1.21),
reported more antihypertensive medications (AOR, 1.10; 95% CI
1.04–1.16), or were living in less deprived areas (IMD (per decile):
AOR, 1.03; 95% CI 1.01–1.05), using multivariable logistic regression
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(Table 2). Conversely, higher BMI (AOR per 5.0 kg/m2, 0.91; 95% CI
0.88–0.95), active smoking (AOR, 0.63; 95% CI 0.51–0.78) and
ownership of an unidentifiable HBPM model (AOR 0.85; 95% CI
0.78–0.93) were negatively associated with active participation.
There were no significant differences in these associations when the
analysis was stratified by age (under 65, 65 years and over).
Interestingly, participants from Scotland (compared to England) and
those who heard about the study via email invitations from health
registries or advertisements (compared to GP invitations) were more
likely to actively participate in BP self-monitoring.
Factors influencing long-term commitment to home BP self-
monitoring
After one year, only 3655 (47.8%) participants were still actively
providing BP measurements, defined previously as submitting at
least six 4–7 day sets of BP measurements (Fig. 1). Continued
submission of BP measurements beyond one year was significantly
associated with increased age at baseline (AOR per decade, 1.26;
95% CI 1.19–1.34) and positive family history of hypertension (AOR,
1.14, 95% CI 1.03–1.26) in the regression analysis (Table 3).
Participants residing in less deprived socioeconomic regions, or
recruited via health registries or advertisements, were more likely to
exhibit a long-term commitment to BP self-monitoring in the study.
Higher BMI (AOR per 5.0 kg/m2, 0.88, 95% CI 0.85–0.92), current
smoking (AOR, 0.58, 95% CI 0.43–0.79) and higher systolic pressure
at baseline (AOR per 1mm Hg, 0.99, 95% CI 0.98–0.99) were
negatively associated with commitment beyond one year of
enrolment. There were no significant differences in these associa-
tions when the analysis was stratified by age (under 65, 65 years,
and over). Owning an HBPM without validation evidence was
associated with a reduced likelihood of continued submission of BP
measurements (AOR, 0.83; 95% CI 0.75–0.91) (Table 3).
Sensitivity analysis for quality of submitted BP measurements
After excluding 353 participants who did not submit BP
measurements that satisfied the predefined validity criteria, 7293
participants had submitted at least one set of measurements. 3428
(47.0%) were still actively providing BP measurements beyond one
year. When limiting the analysis to participants who submitted
valid sets of BP measurements only, positive family history of
hypertension (AOR, 1.09; 95% CI 0.98–1.21) and socioeconomic
status (AOR per decile, 1.02; 95% CI 0.99–1.04) were not
statistically significantly associated with long-term commitment,
although point estimates favoured continued submission of BP
measurements beyond one year.
DISCUSSION
Principal findings
This study provides valuable insights into the medical, social
and economic factors associated with active participation in, and
Table 1. Characteristics of study population enrolled into home BP
self-monitoring in the TIME study.
Characteristic Active participation in BP
self-monitoring study
No Yes
(N= 3413) (N= 7646)
Age (years) – mean ± SD 66.3 ± 9.7 68.5 ± 8.3
Sex – no. (%)
Male 2082 (61.0) 4717 (61.7)
Female 1331 (39.0) 2929 (38.3)
Country – no. (%)
England 3089 (90.5) 6830 (89.3)
Scotland 209 (6.1) 573 (7.5)
Wales 113 (3.3) 242 (2.3)
Northern Ireland 2 (0.1) 1 (0)
Body-mass index (kg/m2) – mean ± SD 31.4 ± 5.9 30.7 ± 5.6
Smoking status – no. (%)
Non-smoker 1934 (56.7) 4498 (58.8)
Current smoker 167 (4.9) 205 (2.7)
Ex-smoker 1301 (38.1) 2906 (38.0)
Unknown 11 (0.3) 37 (0.5)
Co-morbidities – no. (%)
Diabetes 388 (11.4) 845 (11.1)
Angina 119 (3.5) 272 (3.6)
COPD 99 (2.9) 190 (2.5)
Impaired kidney function 121 (3.5) 250 (3.3)
Arthritis 291 (8.5) 734 (9.6)
Peripheral vascular disease 53 (1.6) 91 (1.2)
Myocardial Infarction 157 (4.6) 314 (4.1)
Stroke/TIA 219 (6.4) 467 (6.1)
Family History of HTN – no. (%) 2049 (60.0) 4581 (59.9)
No. of antihypertensive medications – no. (%)
1 medication 1939 (56.8) 4016 (52.5)
>2 medications 1408 (41.3) 3464 (45.3)
Unknown 66 (1.9) 166 (2.2)
Socioeconomic deprivation – no. (%)
More deprived (IMD Decile 1–5) 963 (28.2) 1816 (23.8)
Less deprived (IMD Decile 6–10) 2415 (70.8) 5749 (75.2)
Unknown 35 (1.0) 81 (1.1)
Recruitment method – no. (%)
GP 2626 (76.9) 5505 (72.0)
Health Registries (UK Biobank, GoShare) 474 (13.9) 1413 (18.5)
Hospital/Clinic 105 (3.1) 223 (2.9)
Advertisements 75 (2.2) 214 (2.8)
Characteristics of home BP monitors used
Cuff Site – no. (%)
Wrist 139 (4.1) 346 (4.5)
Upper arm 1984 (58.1) 4770 (62.4)
Unknown 1290 (37.8) 2530 (33.1)
Price – no. (%)
≤ than median (£45.00) 1254 (36.7) 2928 (38.3)
> than median (£45.00) 762 (22.3) 1914 (25.0)
Price not found 107 (3.1) 274 (3.6)
Unknown 1290 (37.8) 2530 (33.1)
Table 1 continued
Characteristic Active participation in BP
self-monitoring study
No Yes
(N= 3413) (N= 7646)
Validation Status – no. (%)
Non-validated BP monitor 374 (11.0) 991 (13.0)
Validated BP monitor 1749 (51.2) 4125 (53.9)
Unknown 1290 (37.8) 2530 (33.1)
BP Blood pressure, COPD Chronic obstructive pulmonary disease, HTN
Hypertension, IMD Index of multiple deprivation, TIA Transient ischaemic
attack.
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long-term commitment to, HBPM measurement in a large UK
remote clinical trial by participants with hypertension. Increased age,
a positive family history of hypertension, a higher number of
antihypertensive medications, and higher socioeconomic status
were associated with active participation in the study. Current
smokers and people with increased BMI were less likely to
participate actively. Participants with non-modifiable risk factors
for hypertension – increased age and positive family history of
hypertension – were also more likely to retain interest and continue
submitting BP measurements one year from enrolment. In contrast,
participants with higher BMI, active smokers or who had higher
systolic pressures at baseline were less likely to submit BP
measurements beyond the first year. TIME Participants recruited
via health registries or advertisements were more likely to actively
participate and maintain engagement in BP self-monitoring.
Meaning of the study
Longitudinal studies are necessary to identify patterns or changes
over time. However, more extensive follow-up periods are
associated with time-dependent increasing risk of attrition [26].
In this study, continued participation in BP self-monitoring at
1-year was 46.2%. Younger age was found to be associated with
lower long-term commitment. Similarly, in a longitudinal
population-based survey of women in Australia, the attrition rate
was higher amongst younger women than middle and older-aged
women [27]. While participants did not actively withdraw from the
TIME study, some were not sufficiently motivated to continue
submitting HBPM-derived measurements. The term “inclined
abstainers” has been suggested to describe such participants,
where positive intentions to engage at the start of the study are
not translated to sustained action [28]. Despite the potential
benefits of the remote study design in reducing the burden of
face-to-face study visits, non-participation and attrition rates for
home blood pressure monitoring were still high. Factors influen-
cing retention in remote studies may be different from those
influencing retention in more traditional site-based clinical trials.
Further work will be needed to understand this better as remote
trials become more common.
The finding that individuals with modifiable cardiovascular risk
factors (smoking, obesity, and higher baseline systolic blood
pressure) are less likely to participate actively or continue engaging
in home BP monitoring beyond one-year warrants further attention.
Other studies have also seen a similar association, and it has been
proposed that more risky lifestyle behaviour is associated with
non-adherence with self-monitoring and interventions [29, 30]. As
younger participants, and those with established modifiable risk
factors, are at increased lifetime risk of cardiovascular events
compared to the general population with hypertension, imple-
mentation of interventions involving self-monitoring of blood
pressure should be accompanied by consideration of additional
efforts to engage them. These efforts could reduce the long-term
negative burden of hypertension and its associated complications
and their impact on the National Health Service finances and
resource allocation.
Socioeconomic deprivation may further complicate the wide-
spread implementation of self-monitoring of hypertension. We
found that residence in less deprived postcode areas was
associated, albeit to a small degree, with increased participation
and continued engagement in home BP self-monitoring. However,
low representation of participants from deprived areas in the TIME
study (6.2% from IMD decile 1 and 2 vs. 33.9% IMD decile 9 and
10) and lower self-reported ownership of HBPMs amongst
deprived individuals (44.4% from IMD decile 1 and 2 vs. 58.0%
IMD decile 9 and 10) may mask true socioeconomic differences in
self-monitoring of blood pressure. For this group of patients,
additional support may be needed.
A detailed analysis of the types and validation statuses of HBPMs
owned by participants in the TIME Study has been previously
described [18]. Concerning only participants who owned identifiable
HBPMs (n= 7239), 81.1% of participants owned a device validated
by BIHS or the dabl Education Trust. The association between
unidentifiable HBPM devices (34.5% of participants) and reduced
participation and long-term commitment to home BP self-
monitoring is concerning. This finding further reinforces the need
to educate people with hypertension on the importance of
incorporating a device’s validation status into decision-making
when choosing an HBPM. Possible reasons that HBPM devices were
unidentifiable include (1) errors in participant reporting (inputting
vendor’s name, brand name with no identifiers of a specific model),
(2) inability to find relevant information on the device, or (3) using
an unbranded home BP monitor.
Strengths and limitations
Participation in self-monitoring of BP in the TIME study was
voluntary; this mirrors everyday HBPM use in clinical care. However,
it is not clear that our findings are directly applicable to the general
population with hypertension. The study investigators had limited
direct communication with participants; only one reminder email
Fig. 1 Consort diagram. BP Blood pressure, TIME Treatment in Morning versus Evening, HBPM Home blood pressure monitor.
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was sent to participants to submit BP measurements regularly.
However, again, this light-touch direction is similar to the clinical
use of home BP monitoring. These pragmatic features of the TIME
study mean that it is more likely that the findings reported here
may be externally valid.
Table 2. Logistic regression of factors associated with active





OR 95% CI OR 95% CI
Age (per decade) 1.03 1.02–1.03 1.29 1.23–1.36
Sex
Female 1 1
Male 1.03 0.95–1.12 1 0.91–1.09
Country
England 1 1
Scotland 1.24 1.05–1.46 1.28 1.08–1.51
Wales 0.97 0.77–1.22 0.99 0.79–1.25
Northern Ireland 0.23 0.02–2.49 0.25 0.01–2.66
Body-mass index
(per 5.0 kg/m2)
0.89 0.86–0.92 0.91 0.88–0.95
Smoking status
Non-smoker 1 1
Current smoker 0.53 0.43–0.65 0.63 0.51–0.78
Ex-smoker 0.96 0.88–1.05 0.95 0.87–1.04
Unknown 1.45 0.74–2.84 1.44 0.75–2.99
Comorbidities
Diabetes 0.97 0.85–1.10 1.02 0.89–1.16
Angina 1.02 0.82–1.28 1.03 0.82–1.31
COPD 0.85 0.67–1.09 0.87 0.67–1.11
Impaired kidney function 0.92 0.74–1.15 0.92 0.73–1.15
Arthritis 1.14 0.99–1.31 1.1 0.95–1.27
Peripheral vascular disease 0.76 0.54–1.08 0.74 0.53–1.07
Myocardial infarction 0.88 0.73–1.08 0.85 0.69–1.05
Stroke/TIA 0.95 0.80–1.12 0.86 0.73–1.02
Family history of HTN 1.06 0.97–1.16 1.11 1.01–1.21
No. of antihypertensive
medications
1.08 1.03–1.14 1.1 1.04–1.16
Socioeconomic status





1.42 1.27–1.59 1.38 1.23–1.55
Hospital/Clinic 1.01 0.80–1.29 1.14 0.90–1.46
Advertisements 1.36 1.04–1.79 1.38 1.06–1.82
Others 1.04 0.85–1.29 1.06 0.86–1.32
Characteristics of home BP monitors used
Validation status
Validated BP monitor 1 1
Non-Validated BP monitor 1.12 0.99–1.28 1.1 0.97–1.26
Unknown 0.83 0.76–0.91 0.85 0.78–0.93
BP Blood pressure, COPD Chronic obstructive pulmonary disease, HTN
Hypertension, IMD Index of multiple deprivation, TIA Transient ischaemic
attack.
Table 3. Logistic regression of factors associated with long-term
commitment to home BP self-monitoring in the TIME study.





Yes (%) No (%) OR 95% CI
N= 3655 N= 3991
Participant Characteristics




Female 1410 (38.6) 1519 (38.1) 1
Male 2245 (61.4) 2472 (61.9) 0.98 0.89–1.08
Country
England 3244 (88.8) 3586 (89.9) 1
Scotland 292 (8.0) 281 (7.0) 1.16 0.97–1.38
Wales 119 (3.3) 123 (3.1) 1.07 0.82–1.40




Non-smoker 2190 (59.9) 2308 (57.8) 1
Current smoker 66 (1.8) 139 (3.5) 0.6 0.44–0.82
Ex-smoker 1383 (37.8) 1523 (38.2) 0.97 0.88–1.08
Unknown 16 (0.4) 21 (0.5) 0.85 0.43–1.65
Comorbidities
Diabetes 386 (10.6) 459 (11.5) 1 0.86–1.15
Angina 118 (3.2) 154 (3.9) 0.84 0.65–1.09
COPD 79 (2.2) 111 (2.8) 0.83 0.61–1.12
Impaired kidney
function
119 (3.3) 131 (3.3) 1 0.77–1.29
Arthritis 344 (9.4) 390 (9.8) 0.95 0.81–1.12
Peripheral vascular
disease
38 (1.0) 53 (1.3) 0.85 0.55–1.31
Myocardial
infarction
144 (3.9) 170 (4.3) 0.94 0.74–1.19
Stroke/TIA 212 (5.8) 255 (6.4) 0.83 0.69–1.01
Family History of HTN
No 1046 (28.6) 1231 (30.8) 1








7.32 (2.3) 7.11 (2.5) 1.02 1.00–1.04
Recruitment method




797 (21.8) 616 (15.4) 1.53 1.36–1.73
Hospital/Clinic 104 (2.8) 119 (3.0) 1.14 0.87–1.50
Advertisements 131 (3.6) 83 (2.1) 1.93 1.46–2.58
Others 143 (3.9) 148 (3.7) 1.18 0.92–1.50
HBPM Characteristics
131.2 (9.6) 132.3 (11.3) 0.99 0.98–0.99
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Our study has some notable limitations. This study comprised
voluntary study participants, a group more likely to exhibit greater
responsibility in their day-to-day chronic disease management.
We hypothesize that the degree of active participation in a real-
world setting may be much lower, particularly considering that
only a third of people with hypertension currently own an HBPM
[15, 16]. The reliance on participant-reported data – baseline
characteristics, information on the HBPM model and longitudinal
BP measurements – was necessary to achieve the efficiency and
cost-effectiveness of undertaking a remote study of this scale. It
does, however, mean that routine validation of these data was not
possible. Although the TIME study has participants from across the
UK, the very small numbers from Northern Ireland mean that
conclusions about country-specific effects may not be general-
izable to Northern Ireland.
Finally, we used the best sources of HBPM validation status
available at the time of analysis, dabl and BIHS. The STRIDE BP
website (www.stridebp.org), since launching in 2019, now
provides an extensive clinically and scientifically supported HBPM
validation status list; this will be an important source of such
information for future similar research [31].
Future research and clinical practice
The costs of an ageing population, rising numbers of people with
long term medical conditions, and the current coronavirus
pandemic are all driving the introduction of telemonitoring in
the UK [32]. Scale-up BP is a project funded by the Scottish
Government to assess the feasibility of implementing telemoni-
toring of blood pressure at scale for patients with hypertension in
primary care [33, 34]. Stoddart et al. showed that supported
telemonitoring of BP was more effective at reducing BP than
standard care but was also significantly more expensive [35].
Results from our study could be used to inform the allocation of
resources in such projects. Individuals at risk of non-participation
or drop-out, e.g., those with modifiable risk factors for cardiovas-
cular disease, might benefit from increased support. This could
reduce loss to follow-up and improve the cost-effectiveness of BP
programmes.
CONCLUSION
A willingness to monitor one’s condition is a prerequisite for
effective self-management. In a large study of participants in a
clinical trial of hypertension in the UK, we have shown that
individuals with non-modifiable risk factors (older age and
family history of hypertension) were likely to participate actively
and remain committed in the longer-term to home blood
pressure monitoring. Conversely, participants with higher BMI,
current smokers or higher systolic blood pressures at baseline
were more likely to stop submitting BP data to the study.
Insights gained from this study should allow future researchers
and clinicians to effectively target follow-up strategies and
minimise loss to follow-up in usual healthcare settings and
remote clinical trials.
Summary table
What is known about this topic?
● Elevated home blood pressure measurements are strongly
correlated with long-term complications of hypertension.
● Supported home blood pressure monitoring can be effectively
used in hypertension management.
What this study adds?
● In a pragmatic clinical trial, patient-level characteristics
affect the likelihood of active and sustained participation in
home blood pressure monitoring using participant-owned
monitors.
● Younger people and those with modifiable cardiovascular
risk factors are less likely to remain engaged with home
blood pressure monitoring after one year.
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